Omeros Corp OMER:NASDAQ

Last Price$2.81NASDAQ Closing Price as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.07(2.43%)
Bid (Size)$2.81 (68)
Ask (Size)$2.82 (19)
Day Low / High$2.76 - 3.00
Volume1.2 M
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/20/2022

 

Omeros Corp ( NASDAQ )

Price: $2.81
Change: -0.07 (2.43%)
Volume: 1.2 M
4:00PM ET 5/20/2022
 
 

Viking Therapeutics Inc ( NASDAQ )

Price: $2.28
Change: +0.01 (0.44%)
Volume: 603.9 K
4:00PM ET 5/20/2022
 
 

Oramed Pharmaceuticals Inc ( NASDAQ )

Price: $4.53
Change: +0.01 (0.22%)
Volume: 546.3 K
4:00PM ET 5/20/2022
 
 

Chimerix Inc ( NASDAQ )

Price: $2.35
Change: +0.15 (6.82%)
Volume: 13.0 M
4:00PM ET 5/20/2022
 
 

Allakos Inc ( NASDAQ )

Price: $3.00
Change: -0.02 (0.66%)
Volume: 611.0 K
4:00PM ET 5/20/2022
 

Read more news Recent News

Omeros Says Results of Study Evaluating Narsoplimab Published in Journal of Clinical Oncology
11:49AM ET 4/20/2022 MT Newswires

Omeros (OMER) said Wednesday the results of a study evaluating the efficacy and safety of its investigational drug narsoplimab to treat hematopoietic stem...

Omeros Q4 Adjusted Loss Widens in Wake of Omidria Sale
5:21PM ET 3/01/2022 MT Newswires

Omeros (OMER) reported a Q4 adjusted net loss of $0.37 per share late Tuesday, compared with a loss of $0.36 per share in Q3. The biopharmaceutical...

Omeros Confirms Submission of Briefing Package to FDA Following Narsoplimab Concerns
4:05AM ET 1/20/2022 MT Newswires

Omeros (OMER) said late Wednesday it has submitted a briefing package to the US Food and Drug Administration after the agency raised concerns about...

--Cantor Fitzgerald Adjusts Omeros' Price Target to $20 From $34, Reiterates Overweight Rating
10:28AM ET 1/18/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionOmeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA. View company web site for more details
AddressThe Omeros Building
Seattle, Washington 98119
Phone+1 206 676-5000
Number of Employees236
Recent SEC Filing05/10/202210-Q
Chairman, President & Chief Executive OfficerGregory A. Demopulos
Chief Financial Officer, Treasurer & VPMichael A. Jacobsen
Chief Scientific Officer & Vice President-ScienceGeorge A. Gaitanaris
Chief Medical Officer & Vice PresidentJ. Steven Whitaker

Company Highlights

Price Open$2.92
Previous Close$2.88
52 Week Range$2.50 - 16.62
Market Capitalization$176.3 M
Shares Outstanding62.7 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings1.04
Earnings per Share-$1.79
Beta vs. S&P 500N/A
Revenue$29.9 M
Net Profit Margin-167.35%
Return on Equity75.62%

Analyst Ratings as of 05/11/2022

Buy
3
Overweight
0
Hold
1
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset